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ABSTRACT
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system
tumor, with median survival after diagnosis of less than 12 months because
dissemination into the brain parenchyma limits the long-term effectiveness of
surgical resection, and because GBM cells are resistant to radiation and
chemotherapy. This sad dismal prognosis for patients with GBM emphasizes the
need for greater understand of the fundamental biology of the disease.
Invasion is one of the major causes of treatment failure and death from glioma,
because disseminated tumor cells provide the seeds for tumor recurrence.
Inflammation is increasingly recognized as an important component of invasion.
In the brain, inflammation can occur by activation of microglia, the resident
macrophages of the brain, or by tumor-associated blood macrophages.
Therefore, we hypothesize that activity of the innate immune system in the brain
can influence tumor progression by secreting cytokines such as Tumor Necrosis
Factor alpha (TNF-α). In this study, we show that patient-derived glioma spheres
undergo morphological changes in response to TNF-α that are associated with
changes in migration behavior in vitro. These morphological changes include
appearance of tumor islands in site different from where the primary tumor cells
were seeded. We further showed that TNF-α treated cells significantly increased
expression of cell adhesion molecules such as CD44 and VCAM-1. Furthermore,
we demonstrate increased cell density also caused increased in expression of
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cell adhesion molecules. The extent to which these are recapitulated in vivo will
be investigated.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND INFORMATION

Introduction
Glioblastoma multiforme (GBM) is the most lethal primary tumor of the central
nervous system (CNS), with median post-diagnosis survival of less than 12
months [1, 2]. The dismal prognosis of GBM patients necessitates achieving a
better understanding of the fundamental biology of this disease.
The invasive nature of GBM plays a major role in treatment failure and death,
such that disseminated glioma cells provide the seeds for tumor recurrence.
Inflammation is increasingly recognized as a central factor of brain responses to
brain tumors; inflammatory cells are important components of the tumor
microenvironment, promoting tumor survival and migration [3]. Inflammatory
responses in the brain can occur by activation of either microglia (the resident
macrophages of the brain), or tumor-associated macrophages. Previous studies
show that certain innate immune system-associated signaling molecules and
their receptors have been co-opted by tumor cells for invasion. Tumor Necrosis
Factor-alpha (TNF-α) and its receptor (TNFR1 and TNFR2) are examples of such
molecules [3].
The aim of the present study is to investigate the role of TNF-α on patient-derived
GBM cells. Our preliminary data show a trend of morphological changes in GBM

cells following in vitro TNF-α treatment. Further analysis shows that these
morphological changes are associated with alterations in GBM cells’ migratory
behavior. Another significant observation of this study reveals up-regulation of
different cell surface molecules on GBM cells as a downstream effect of TNF-α.
VCAM-1 and CD44 in particular are among these cell adhesion and receptors
molecules examined in the present study (Mahadev et al., submitted).
Furthermore, decreased expression of Ki67 in TNF-α treated GBM cells indicate
effects of TNF-α on proliferation.
Moreover, our results provide evidence suggesting the potential role of the
density of cultured cells in initiation of GBM cell invasion; this is based on the
observation of the positive correlation between Ki67 expression and cell density,
independently of TNF-α. The extent to which these mechanisms are active in
vivo will be subject to future investigation. Besides, our observations demonstrate
the possible role of cell density in and the formation of secondary islands,
emphasizing on the effects of increased cell-cell adhesion in secretion of different
cytokines.

Background
The term "glioma" refers to tumors that exhibit histological features similar to
those of normal glial cells (astrocytes, oligodendrocytes) and ependymal cells.
Astrocytomas account for 80–85% of all gliomas. The World Health Organization
2

(WHO) classifies glioma into four different grades, counting grade IV glioma, also
called GBM, as the most aggressive and grade I glioma as the least aggressive
type.
Unfortunately, despite major breakthroughs in cancer research, the prognosis of
malignant glioma patients remains dismal, owing to traits distinct to GBM. The
main characteristics of gliomas responsible for their lethality and inefficacy of
most treatments include their ability to diffuse and infiltrate throughout the brain
parenchyma, their robust angiogenesis, which is consequent of their invasive
behavior and their intense resistance to apoptosis, as well as their genomic
instability [4, 5].
Different factors could cause heterogeneity of GBM. Initially it was believed that
genetic chaos is the main source of GBM heterogeneity. Further studies have
also attributed heterogeneity to diversity in the tumor microenvironment which
could cause development of different cell types (described in Figure 2) [4]. There
is growing evidence suggesting that rather than being simple bystanders,
different tumor cell populations are capable of establishing a complex network of
interactions between each other and within the tumor microenvironment, which
supports tumor growth by establishing a glioma niche over time [6].
For many years the relationship between tumor cells and tumor
microenvironment has been modeled as the relationship between the seed and
soil, since soil can have significant effects on the growth of the seed. The effects
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of tumor microenvironment on tumor progression have been emphasized in
almost all kinds of tumors, including glioma [7]. Microglia, as a part of the innate
immune system, are involved in creation of the tumor microenvironment, thereby
influencing tumor angiogenesis and invasion. They are the resident
macrophages in brain tissue and are important contributors to tumor progression
[7]. They contribute substantially to the tumor mass of glioma. They stay in a
quiescent stage under normal brain conditions. Upon activation, stimulated by
brain injury or tumor formation, microglia initiate inflammatory pathways and
secrete different cytokines. Interestingly, tumor cells have the ability to co-opt
microglia secreted cytokines in their own favor, and use them in their growth and
invasion [8]. TNF-α is an important example of cytokine secreted by activated
microglia. The objective of the present study is to investigate the effect of
activated-microglia-secreted pro-inflammatory cytokines, such as TNF-α, on
glioma cells’ invasive behavior. To that end, the morphological effects of TNF-α
on patient derived GBM cells as well as its effects on cell proliferation and cell
adhesion molecules including Ki67, VCAM and CD44 as a cell-cell interaction
marker were studied.
Heterogeneity Maintenance in Glioblastoma
As is mentioned, GBM is defined by different characteristics; each of them alone
or in combination could be a potential cause of the high mortality rate in this
disease. Among these characteristics is its striking cellular heterogeneity [9]. Due
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to this inherent trait, a single tumor mass within one patient consists of population
of cells with different biolog
biological features. As shown in Figure 1,, a single tumor
bulk typically consists of Tumor Initiating Cells (TIC), the tumor cells, microglia as
a part of the innate immune system, and different cytokines secreted into the
tumor microenvironment during the infla
inflammatory response [9].. TICs, known to
promote the therapeutic resistance and tumor angiogenesis [10, 11],
11 provides the
seeds for tumor invasion and its dissemination through the brain parenchyma.
parenchyma

Figure 1. GBM tumor core and invasive cells in the context of cells found in the brain
parenchyma. Invasive glioblastoma multiforme cells (dark nuclei) secrete various autocrine
motility factors that support the process of invasion. Cells in the central nervous system (CNS)
express cognate receptors for ligands secreted by GBM cells, which enable communication
commun
between glioblastoma multiforme cells and the normal cells in the path of invasion (reproduced
from [12]).
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Innate Immune System.
Similar to other systemic organs, the central nervous system (CNS), promotes a
critical immune response against pathogens and cell debris [13]. In the brain this
response is developed by innate immune system based upon the activation of
the resident microglial cells. An evidence for that is the infiltration of Tlymphocytes and antigen presenting cells (APC) during a variety of CNS
pathologies, such as multiple sclerosis and glioma [13]. In addition to resident
APCs and macrophages, microglia are also key players in coordinating this
system of active surveillance [14].

6

Figure 2. Heterogeneity origins and maintenance. A, according to clonal evolution,
heterogeneity is caused by the acquisition of mutations and expansion. Upon a selective
pressure, such as drug treatment, more adapted clones survive and, through consequent
mutations, give rise again to a heterogeneous population. B, the CSC model postulates that only
CSCs are able to divide indefinitely, giving rise to cells that will differentiate heterogeneously.
CSCs can also acquire mutations and generate a heterogeneous CSC population. CSCs are
considered to be drug resistant, such that surviving cells serve as a reservoir for tumor relapse.
C, whether heterogeneity arises by clonal evolution, CSCs, or CSCs undergoing clonal evolution,
its maintenance requires interactions between CSCs and/or tumor cells and their
microenvironment and between different CSCs and/or tumor cell clones. Those interactions can
drive an increase in tumor growth, drug resistance, immune suppression, angiogenesis, invasion,
or even CSC renewal (reproduced from [4]).
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Through intimate relationships with the surrounding microenvironment, microglia
maintain a quiescent phenotype in the normal CNS. In the context of CNS insult
or injury, microglia convert to an active phenotype, with increased
proliferation, motility, phagocytic activity, and the release of cytokines and
reactive oxygen species. Activated APCs and microglia have similar roles to
macrophages in peripheral tissues, serving as essential components of both the
innate and adaptive immune responses. In addition to lymphocytes, microglia
have also been found in CNS disease processes, including tumors of the CNS
[14, 15].
One of the characteristic features of microglia is their rapid activation in response
to injury, inflammation, infection, and brain tumors [16]. Microglia are an
abundant portion of the CNS cell population, comprising 5% to 20% of the total
glial cell population, and in normal brain are as numerous as neurons [14].
Activated microglia in CNS mediate inflammatory responses which are an
important property of brain pathology and cancer. During inflammation, microglia
secrete different cytokines and chemokines which can be co-opted by different
tumor cells. In regards to the brain, it remains controversial whether the
inflammatory response elicited by microglial cells are beneficial or detrimental to
various tumors’ survival. The chronic activation of microglia may cause neuronal
damage through the release of potentially cytotoxic molecules such as
proinflammatory cytokines, reactive oxygen intermediates, proteinases and
complement proteins. On the other hand, in a variety of CNS pathologies, such
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as infection, injury, and neurodegenerative disease, [WHAT??] cause the
activation of the resting ramified microglia by detecting proinflammatory
cytokines. Therefore, suppression of microglia-mediated inflammation has been
considered as an important strategy in neurodegenerative disease therapy [17].
For example, activated microglia express Toll-Like Receptors (TLRs) and initiate
innate inflammatory responses through secretion of cytokines, chemokines and
nitric oxide (NO). Cytokines released by activated microglia that are in the scope
of this study include interleukin (IL)-1, IL-6 and TNF-α [14].

Tumor Necrosis Factor α (TNF-α)
Human TNF-α is a trans-membrane protein, composed of 233 amino acids, of
which 35 amino acids form its cytoplasmic domain, 21 amino acids its
transmembrane segment, and 177 amino acids its extracellular domain (ECD).
The soluble form of this protein is produced by the matrix metalloproteinase TNFα converting enzyme (TACE), which is responsible for cleaving TNF-α from the
membrane and producing the soluble form of TNF-α. TNF-α was first identified in
the late 1970’s as a potent pro-inflammatory and immune-modulatory cytokine,
implicated in inflammatory conditions such as cancer [18]. Since the TNF-α gene
was cloned in 1984, extensive research has revealed a variety of roles for TNF-α
under physiological and pathological conditions; some examples of such roles
include immunity under physiological conditions and inflammation under
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pathological
ological conditions. TNF
TNF-α is produced by macrophages and T-cells
T
as well
as microglia cells. Interestingly
Interestingly, TNF-α, as well as IL-1, stimulates its own release
from the membrane of the activated microglia cells.
On the cellular level, TNF
TNF-α exerts its effects through its receptors to activate
distinct signaling pathways. These signaling pathways include the PI3K and
eventually NF-κB
B pathways resulting in expression of VCAM
VCAM-1 as well as the
ezrin, radixin and moesi
moesin (ERM) phosphorylation and interaction with CD44 and
increased expression of hyaluronan, a major extracellular matrix component [19,
20].

Figure 3. Downstream effects of TNF
TNF-α in the regulation of VCAM-1 and CD44 expression.
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TNF-α and VCAM-1
VCAM-1, or cluster of differentiation 106 (CD106), is a cell surface protein
expressed by macrophages and activated endothelial cells. It is a member of the
immunoglobulin superfamily. Activation of the receptors for TNF-α on target cells
such as endothelium mediates the upregulation of cell adhesion molecules
including VCAM-1, leading to leukocyte migration and accumulation at the site of
inflammation. VCAM-1 is a ligand to leukocyte integrin VLA-4 and is thought to
cooperate with CD44 in cell migration [21, 22] . The schematic in Figure 3 shows
the downstream effects of TNF-α in the regulation of VCAM-1 expression.
As shown, the function of TNF-α is caused by several signal transduction
pathways that are activated by the interaction of TNF-α with TNF receptor 1 and
receptor 2 (TNFR-1, TNFR-2) [23]. Activation of these receptors trigger
intracellular signaling cascade which leads to PI 3-kinase (PI3K) activation and
subsequent Akt phosphorylation. The activated Akt will in turn activate NF-κB as
well as MAPK signaling cascades. One of the targets for these signaling
cascades is transcription of VCAM-1, a major endothelial ligand increasing cell
adhesion. Therefore, activation of MAPK and NF-κB will ultimately result in
VCAM-1 gene expression and protein production [5, 23-27].
TNF-α and CD44
The underlying molecular mechanisms of GBM invasion are complex and involve
integrated biochemical processes requiring a coordinated effort of intracellular
11

and extracellular interactions. For effective invasion, tumor cells must first detach
from the nascent tumor mass and invade the surrounding stroma, which is
composed of parenchymal cells and Extra Cellular Matrix (ECM). One
downstream effect of activated microglia- released cytokines, including IL-1α, IL6 or TNF-α, is increased expression of cell adhesion molecules (CAM). To
illustrate, the presence of these cytokines near blood vessels stimulates the
endothelial cells, thereby, cause increased expression of cell adhesion molecules
including VCAM-1. This will eventually seed the invasion of GBM.
CAMs play an important role in the interaction between the cells and ECM and
are expressed on a variety of cells, including vascular endothelial cells (ECs) and
tumor cells. One of the main components of ECM is hyaluronan (HA), which
mediates cell attachment to other cells or ECM. The cell surface receptor for this
molecule is CD44 that is believed to be a TIC marker [28]. CD44 has been
implicated in the progression, adhesion and invasion of a variety of cancer types,
including ovarian and GBM, and its depletion blocks GBM growth and sensitize
GBM cells to cytotoxic drugs in vivo [25, 29]. HA is extruded to the extracellular
space after being produced by Hyaluronan synthase (HAS) enzyme. HAS
transcription is promoted by protein kinase C (PKC) which is activated by TNF-α.
TNF-α can also indirectly promote the transcription of HAS. The binding of HA to
the extracellular domain of CD44 receptor promotes the interaction between
CD44 and the cytoskeletal proteins including ERM [30]. As it is also shown in
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Figure 3, the downstream effects of TNF-α on PKC and HAS transcription
eventually cause elevation of cell surface receptor CD44.
Consequently increased expression of TNF-α increases the hyaluronan-CD44
interactions, which in turn will increase the CD44–phosphorylated ezrin-radixinmoiesin (ERM) family through PKC activation [31, 32]. The result of these
interactions is the promotion of cell invasion, cell adhesion and cell motility
through induction of cytoskeletal changes. These changes are induced by actin
filaments that are joined to the cytoplasmic tail of CD44 via members of the ERM
family [33].

Research Overview
In an effort to understand the mechanism underlying the GBM invasion, it is
necessary to understand the role of cytokines, present and secreted in the tumor
microenvironment by activated microglia. One of the main secreted cytokine by
microglia is TNF-α. To that purpose, different migration assays are used to
understand the effects of TNF-α on GBM dissemination by measuring the cell
adhesion molecules as well as comparing the morphological changes cause by
TNF-α. The cell adhesion molecules that are focused in this study are VCAM-1
and CD44. The ICC protocol is followed to stain the migrated cells, and the
experiment condition is kept constant through the entire experiment so that the
images, taken by the confocal microscope, could be compared with each other.
13

In order to quantify the data, using Image-pro software the light intensity of the
images are measured and using the Microsoft Excel, the light intensity of 80% of
the pixels (Lum80) are calculated. The expression of different markers in
response to TNF-α concentration was compared by comparing the Lum80 of
each group.
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CHAPTER TWO
MATERIALS AND METHODS

Tissue Culturing
Patient-derived glioma cell lines (PBT003;[34]) were maintained in DMEM/F-12
medium supplemented with B27 (1:50), 1% L-Glutamine, 1M HEPES, 1%
Pen/Strep and 1 mM Heparin Sodium solution. Cultures were supplemented with
0.02 µg/mL of Epidermal Growth Factor (EGF) and 0.02 µg/mL of Fibroblast
Growth Factor (FGF) every 3 days. Cultures were grown in 5% CO2 humidified
incubator at 37°C and passaged every 3–5 days. Cells were ready for
experiments when they reached 70% confluency.
Working with low passage-number cells (less that 10) was considered as an
important factor in this study. It was due to the fact that PBT003 cells had a
tendency to adhere more to the surface by increasing the passage number.
Therefore, to keep the cells in close passage numbers to each other between
study replications, the cells were frozen down and new sets of cells were thawed
several times. Therefore, in all biological replications the cells were in passage
numbers 7-10.
PBT003 cells were cryopreserved for long-term storage in liquid nitrogen. The
cryopreservation protocol was as follow: cells were collected via centrifugation at
1200 RPM for 5 minutes, followed by removing of the supernatant, using sterile
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pasture pipette and then re-suspending the cell pellet in 1 mL of Non-enzymatic
Cell Dissociation Solution (NECDS). The cells were then incubated for 5 minutes
or until single cell suspension was reached, after which they were diluted in
DMEM. Next the viability and density of the sample was determined by using the
Nexcelom Cellameter Auto T4 cell counting machine. Then the cells were
centrifuged for 5 minutes at 1200 RPM. The supernatant was then discarded and
the cell pellet was re-suspended in cold cryopreservative medium at the final
concentration of 106 cells/mL. Cryopreservative medium consisted of 10%
dimethylsulfoxide (DMSO) and 90% fetal bovine serum (FBS). Then 1 mL of the
cryopreservative medium containing 106 cells was added to the cryovials and
immediatly placed in -20°C freezer for two hours, then transferred to -80°C
freezer overnight, followed by their long-term storage in liquid nitrogen.
In order to thaw the cells, the cryovial containing PBT003 cells was placed into
37°C water bath for about 30 seconds for quick thawing of the cells. While a
small chunk of frozen cells still remain, the cryovials were removed from the 37°C
water bath and the cells were transferred into media. The cells, diluted in the
medium, were centrifuged for 5 minutes at 1200 RPM, the supernatant was
removed, and the cells were re-suspended in the final medium in 106 cells per mL
density and supplemented with EGF and FGF and grown in the incubator.
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Boyden Chamber Cell Migration Assay
The migration assay was performed using a transwell chamber system (24-well
format; MilliPore, USA) with 8 µm pores. Following the schematic in Table 1,
PBT003 cells were plated at the upper chamber, or both lower and upper
chamber of the transwell chamber system. The cells were seeded at 106 cells in
800 µL in the plate and 5×105 cells in 200 µL into the upper compartment of the
insert. The medium containing the cells were placed in the upper chamber first,
and then the lower chamber was field with the media. This was to avoid
immediate mixing between the two chambers.

Upper
Cells
Cells
chamber
Lower
(medium Cells
chamber
only)

Cells

Cells

Cells

HA

Cells +
TNF-α
HA

Cells

Cells

Cell +
HA
+
HA
+
TNF-α
TNF-α

Table 1. The pattern followed in plating the cells in the Boyden chambers. Cells are plated
in PBT003 medium in the upper chamber of all conditions to see their migration through the pores
towards the different conditions in the lower chamber. The lower chamber were field with the
medium supplemented with different conditions of TNF-α alone or in combination with HA or with
the cells

The cells in both chambers were seeded with 1.5% Matrigel to have all the cells
attached to the surface and avoid formation of glioma spheres. HA was used in
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the lower chamber at 50 mg/mL, and TNF-α at 20 ng/mL. The chambers were
then incubated at 37°C for 18 hours.

Crystal Violet Staining of Migrated Cells
After 18 hours of incubation, the inserts were removed from the plate and fixed
with 95% ethanol for 30 minutes followed by washing with distilled water twice.
The cells were then stained with 0.2% crystal violet for 30 minutes after which
they were washed with distilled water three times. Then, using cotton swabs, the
cells that were on the upper surface of the membrane were removed. Then the
membrane was separated from the insert using a sharp pointed blade and placed
on a slide. Using Prolong Gold mounting solution (Invitrogen), the membrane
was fixed between the slide and the cover slip. The entire lower surface was then
imaged by tilling the field using a 4x objective. Crystal violet stains nuclei dark
purple, and the total number of migrated cells was counted by thresholding the
nucleus color using ImagePro software.

Dot Migration Assay
The experiment starts when PBT003 cells were about 70% confluent after at
least 4 to 5 days of being passaged with mostly tumor spheres suspended in
culture rather than single cells. PBT003 cell spheres were centrifuged for 5
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minutes at 1200 RPM. The pellet then was re-suspended in NECDS for 5
minutes in a 37°C incubator or until a single cell suspension was approached
after gentle trituration. Cells were then re-suspended in DMEM/F12 medium and
counted. Next PBT003 cells were centrifuged for 5 minutes at 1200 RPM and resuspended at range of 5 x 104 to 5 x 106 cell/mL. Then the cells were resuspended in DMEM/F12 medium supplemented with 3% BD Matrigel basement
membrane matrix. 10µL of the cell suspension was taken (500-50,000 cells total)
and plated as a dot on cover slips in 24-well plates. The cells were then placed in
the incubator so they would attach to the cover slip. A minimum of one row of
wells of the 24-well plate was filled with DMEM/F12 medium to keep the plate
humid enough so that the 10 µL drop of the cells would not dry. After four hours
of incubation, each well was filled with 500 µL of DMEM/F12 medium with 2.5-20
ng/mL TNF-α plus 3% Matrigel. The number of the cells on cover slip and the
study design is shown in Figure 4. M indicates that the row is filled with medium
to keep the plate humid. The control population was filled with the same condition
without TNF-α. After three days of incubation, the cells were fed with fresh
medium having the same condition as in the beginning of the experiment. On day
six of the experiment the cells were fixed and prepared for Immunocytochemistry
(ICC).
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Immunocytochemistry Analyses
After six days of incubation, the cells were fixed with 500 µL of 4%
Paraformaldehyde (PFA) in Tris-buffered saline (TBS) for 30 minutes at room
temperature. After fixation, cultures were washed three times with wash solution
(TBS + 0.1% Triton X-100) (Triton X-100 is used to permeabilize the cells), and
then incubated with blocking solution (50% Western blocking reagent + 50%
BlockAid (Invitrogen) solution + 1% Triton X-100) at room temperature for one
hour.
Then the blocking solution was replaced with the primary antibody solution
(diluted in blocking solution). The primary antibody solutions used include; CD44,
obtained from Abcam (USA), VCAM, obtained from R&D Systems (USA), and
Ki67, obtained from Leica Biosystems (USA). The primary antibodies were
diluted in 1:40, 1:200 and 1:100 respectively and incubated at 4°C overnight. The
coverslips were then washed with washing solution three times and incubated
with secondary antibody solution (diluted in blocking solution) in the dark at room
temperature for two hours. The coverslips were then washed with washing
solution three times and counterstained with Hoechst, diluted in washing solution,
for 15 minutes. The coverslips were then washed and mounted in Prolong Gold
antifade reagent. After two days at room temperature in the dark the cultures
were ready for imaging. Figure 5 is the schematic illustration of these steps.

20

Cell density

Cell density

A

500

103

5x103

104

5x104

500 10

3

3

4

5x10 10 5x10

4

M
M

10

20

control M

TNF-α concentration (ng/mL)

2.5

TNF-α concentration (ng/mL)

5

One well of a 24-well

B

Cover
10µl of cells with

Figure 4. The study design to perform the dot migration assay on PBT003 cells. A) Cells are
plated at different concentrations with different concentrations of TNF-α. Each plate has a
minimum of one row of wells field with DMEM/F2 medium to keep the inside of the plate humid
and avoid evaporation of the 10 µL cell bubble. M indicates the medium. B) the schematic of the
cells plated in the experiment
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Fixation and block

Primary antibody

Secondary antibody

Prolong Gold
Hoechst solution

Figure 5. Schematic of fluorescent ICC staining of PBT003 cells on coverslips.
After six days of incubation, the cells are fixed, blocked and stained with primary and
corresponding secondary antibody. Then, in order to stain the nucleus, the cells are stained with
Hoechst solution and mounted on the slide using Prolong Gold. After being incubated in room
temperature, slides are ready to be imaged. In this experiment the slides are imaged using Zeiss
LSM 700 inverted confocal microscope
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Imaging
Images of the coverslips were taken using a Zeiss LSM 700 inverted confocal
microscope, with tiling to image the entire culture. The cells were stained with
secondary antibodies with fluorescent molecules that excite at 488, 555 and 647
µm wavelengths. These secondary antibodies were made in donkey and were
utilized to detect the Ki67, VCAM-1 and CD44 primary antibodies that were made
in rabbit, goat and mouse respectively. The coverslips were then imaged with a
10x objective (Zeiss Fluar 10x).
All samples were imaged using standard configurations of the Zeiss Zen
software. Pinhole size which prevents unwanted light to reach the detector was
set to 1 Airy Unit (AU) for best compromise between depth discrimination and
detection sensitivity.

Time Lapse Imaging
Using Zeiss AxioVision software in the Zeiss AxioObserver Z1 inverted
microscope, a time lapse sequence of the dot migration assay was taken for the
first three days of experiment. This microscope has a large heated enclosure,
heated stage insert, and CO2 control. The cells survived for 3 days in the
enclosed stage of the microscope, and tiled phase contrast images were taken
from defined positions every 20 minutes. A movie of the cell movements was
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made using ImagePro software. In this experiment the movements of the cells in
control samples were compared to those treated with 20 ng/mL of TNF-α.

Data Analyses
All images in each experiment were taken with the same master gain, digital
offset and digital gain settings. Therefore, changes in fluorescence intensity of
the samples could be directly compared.
Images were analyzed using the ImagPro software. Images were taken in 8 bit
pictures resulting in 256 possible shades of color from 0 indicating as darkest
and 256 as brightest. Fluorescence intensity was measured and transferred to
Microsoft Excel. Zero intensity was considered as background and was
eliminated from the calculations. The relative light intensity collected from each
pixel was normalized by dividing the number of pixels expressing the same light
intensity to the total number of collected pixels. This would provide the proportion
of pixels. The cumulative probability showed the sum of number of the proportion
of pixels that have light intensity below the measuring level. The cumulative
probability of all data would eventually equal to 1 which means 100% of the data
were covered. Next, the luminance density of 80% (Lum80) was calculated to
show the light intensity of 80% of the pixels. Higher Lum80 indicates brighter
pixels and therefore higher expression of the antigen. An illustration of the data
analysis is shown in Table 2.
24

Expression (light
intensity)
(Background) 0
1
2
3

Number
pixels
A
B
C

of Proportion of Light
intensity
0
A / (A+B+C) = D
B / (A+B+C) = E
C / (A+B+C) = F

Cumulative
probability
0
D+0=G
E+G=H
F+H=I

Table 2. An illustration on analyzing the fluorescence intensity of the stained ICC samples.

Statistical Analyses
The experiments were carried out in duplicate biological replication and data
presented are representative of the independent experiments. Statistical
significance was determined by the one way ANOVA with P value ≤ 0.05 as a

threshold for significance.
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CHAPTER THREE
RESULTS

The contributions of TNF-α to cell dissemination were investigated using different
migration and invasion assays. To this end, a Boyden chamber migration assay
was performed as the initial steps of the study.

Boyden Chamber Migration
The results of this study have shown that HA causes an increase in glioma cell
migration across the insert membrane, whereas increased amounts of TNF-α
significantly decreased glioma migration. Furthermore, migration of cells treated
with HA + TNF-α is less than the control, as shown in Figure 6. Moreover, it is
shown that HA and TNF-α caused morphological changes in the cells compared
to the control population. It was observed that TNF-α treated cells were more
adherent to each other than the non-treated control cells, which exhibited more
flat and spread cell morphology, suggesting TNF-α is possibly effecting through
signaling pathways that result in cell adhesion.
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A

C

B

Figure 6. The effects of TNF
TNF-α and HA in cell migration assay. A) HA, alone in the lower
chamber showed slight increase in the cell number but was not statistically significant. TNF-α,
TNF
however, significantly decrease the number of cells migrated though the 8 micron pores. B)
Morphology of the PBT003 cells with no treatment. It shows how the cells are flat and spread
sprea out.
C) Shows the morphology of the cells after being treated with TNF
TNF-α for six days. The cells have
a pointy morphology and they have adhered to each other. (Measurements were made in
triplicate in each of three independent experiments)
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Therefore to stimulate
timulate the 3D tumor environment in-vitro, the dot migration assay
was conducted. Figure 7 explains the similarity between the 3D tumor
microenvironment and our experiment. In this regard the cover slip imitates the
blood vessel and the 3% Matrigel mimics the ECM.

Figure 7. Similarity of our experiment
experimental arrangement to the in vivo tumor environment. The
same as in tumor environment, in which the GBM cells would move along with the blood vessels,
the PBT003 cells move along with the cover slip in the ECM simulated by the Matrigel.

The E
Effects of TNF-α on Tumor Dissemination
The primary observation of the TNF
TNF-α treated cells was the significant cell
dissemination compared to the control group. Figure 8, shows phase contrast
imaging of PBT003 cells in primary dot after 18 hours of incubation (Figure 8, A
and C) and the disseminated cells after 72 hours of incubation (Figure 8, B and

28

D). In this figure the control group (Figure 8, A and B) show the proliferation of
the cells in a compact pattern whereas the treatment group with 20 ng/mL of
TNF-α (Figure 8, C and D) shows the increased cell-cell adhesion and
dissemination. The fluorescent images of dissemination in PBT003 cells treated
with TNF-α is shown in Figure 9. In this figure, the VCAM-1 expression of the
cells in the control non-treated cells (A) and in the cells treated with 20ng/mL of
TNF-α for 6 days (B). In order to visualize the shape of the control sample and
the dissemination pattern of the TNF-α treated cells, the brightness of both
samples was increased to saturate the TNF-α treated cells.. The cells in the
control group grew in a monolayer following the primarily dot shape, however,
cells treated with TNF-α have migrated and made satellite-shaped secondary
colonies. Furthermore, these cells have adhered to each other and disseminated
toward different random directions.
The number of satellite shaped secondary colonies that are made due to the
effects of TNF-α are presented in Table 3.

The Effects of TNF-α on VCAM-1 Expression in PBT003 Cells
The expression of VCAM-1 and CD44 in different densities of GBM cells treated
with different concentrations of TNF-α was measured using confocal microscopy.
The preliminary results show an increase in the expression of both VCAM-1 and
CD44 in GBM cells treated with TNF-α.
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Figure 9 is a 6.40cm x 6.40cm image size for the control group (A) and 7.04cm x
7.04cm image size for the treatment group (B) comparing the VCAM-1
expression in PBT003 cells treated with 20ng/mL of TNF-α for six days. As is
shown, the cells treated with TNF-α are brighter compared to control group
meaning that the VCAM-1 expression in these cells is higher.
In order to quantify the data, as described in Table 2, the light intensity of each
pixel is measured using Image Pro software. Then the data is normalized to
provide the proportion of light intensity. Figure 10 compares the proportion of
light intensity of PBT003 cells treated with TNF-α and control. The magnified
graph in part B of this figure indicates that higher number of pixels in control
group express lower light intensity whereas more pixels express higher light
intensity for TNF-α treated cells. Even though each pixel is not a representative
of a cell (cells are much bigger) increased light intensity in higher portion of pixels
indicate higher expression in that group.
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A

B

C

D

Figure 8. Phase contrast imaging on PBT003 cells. Cell dissemination and adhesion can be
seen in as short as 18 hours after TNF-α treatment. A) The control group after 18 hours of
primary dot of cells is placed. B) The control group after 3 days of incubation. C) The treatment
group after 18 hours of incubation with TNF-α. D) The same group as in C after incubation with
TNF-α for three days
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B

A

1cm

E

D

C

Figure 9. The effects of TNF-α on GBM dissemination. The image shows the VCAM-1
3
expression of PBT003 cells initially seeded with 5x10 cells A) in the control, non-treated cells
and B) in the cells treated with 20ng/mL of TNF-α for 6 days C, D and E are Further examples of
GBM dissemination and satellite formation of PBT003 cells treated with 10ng/mL of TNF-α. The
6
6
5
initial cell density is 5x10 , 10 and 5x10 respectively.

The number of cells the study start with

The TNF-α
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concentration

that

the

new

satellite colony was observed
4

10ng/mL (X2), 5ng/mL

5x10 cells
4

20ng/mL, 10ng/mL(X2),, 5ng/mL, 2.5ng/mL

10 cells
3

20ng/mL (X2), 10ng/mL(x2),, 2.5ng/mL

5x10 cells
3

10 cells

Nothing

500 cells

Nothing

Table 3.. The number of satellite shape secondary colonies made as a result of TNF-α
TNF
treatment

A

0.9

Control

20ng/mL TNF

PROPORTION OF PIXELS

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

100
LIGHT INTENSITY

0.9

Control

200

20ng/mL TNF

PROPORTION OF PIXELS

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

5

10
15
LIGHT INTENSITY

20

25

6

Figure 10. Proportion of pixels for VCAM expression in 10 PBT003 cells
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In order to better compare the data, the cumulative probability of the proportion of
pixels are measured as in Table 2. To illustrate, the pointer in Figure 11, points to
the 0.8 cumulative probability of the control and treatment group. In this example,
the 0.8 cumulative probability of the control population is close to 1 whereas this
number in TNF-α treated population is close to 50, indicating that expression in
cells treated with TNF-α is higher compared to control.

1.2
Cumulative probability

1
0.8
0.6

Control

0.4

20ng/mL TNF

0.2
0
0

50

100
150
Light Intensity

200

250

6

Figure 11. Cumulative probability for VCAM expression in 10 PBT003 cells

A method to compare the results would be to use the cumulative probability of
the 0.8 data (Lum80). This means to compare the light intensity of 80% of
population with each other. Therefore, in this study the results of the experiments
are compared using the Lum80 of the data.
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The Effects of Different Concentrations of TNF-α on VCAM-1 Expression of
PBT003 Cells
Increased concentration of TNF-α tends to significantly increase the expression
of VCAM-1 in these cells (P value <0.0002). As is compared in Figure 12 the
Lum80 of the cells treated with 20 ng/mL TNF-α is increased in all different cell
densities compared to the control group. However, the increased expression of
VCAM-1 in the group with 104 cells to begin with is higher compared to all other
cell densities. Moreover, the group with lowest cell density to begin with, 500
cells, has the lowest increase in the expression of VCAM-1 in response to TNF-α
treatment.

A

The effects of TNF-α concentration of VCAM-1
expression

VCAM-1 (Lum 80)

30

500 cells

25

1000 cells

20

5000 cells

15

10000 cells

10

50000 cells

5
0
0

5

10

15

20

TNF-α concentration (ng/mL)

35

25

B

Trend line of the effects of TNF-α concentration
of VCAM-1 expression

VCAM-1 (Lum 80)
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5
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0
0

5

10

15

20

25

TNF-α concentration (ng/mL)

C
**

**

***

***

Figure 12. The effects of increased TNF-α concentration on VCAM expression of PBT003
cells. A) Increased TNF-α concentration caused increased expression of VCAM-1 in PBT003
cells with all cell densities. C) The One-way ANOVA test result shows (P value <0.0002)
significant increase in VCAM-1 expression in cells treated with all different concentrations of TNFα.
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The Eeffects of TNF-α on VCAM-1 Expression of Different Densities of PBT003
Cells
The results of this experiment, shown in Figure 13, indicate that cell density could
also be an important factor in invasion behavior of PBT003 cells. As
demonstrated in this figure, although the overall trend of the graph is increased
expression of VCAM-1 due to increased cell density, the group with initial density
of 5x104 cells reached a plateau and did not show any more increase in VCAM-1
expression. Furthermore, at 20ng/mL concentration of TNF-α, VCAM-1
expression is decreased in groups with the initial seeding density of 5x104 cell,
compared to the group with 104 cells initial density.

The effects of cell density on VCAM-1 expression of
PBT003 cells

VCAM-1 (Lum 80)

30
25
20

Control

15

2.5 ng/mL TNF-α

10

5 ng/mL TNF-α
10 ng/mL TNF-α

5
0
5.00E+02

20 ng/mL TNF-α
5.00E+03

5.00E+04

Cell density

Figure 13. The effects of different TNF-α concentrations on VCAM-1 expression of
PBT003 cells in different densities
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The Effects of TNF-α on CD44 Expression of PBT003 Cells
PBT003 cells cultured at different densities are treated with different
concentrations of TNF-α ranging from 2.5-20 ng/mL for six days. The results of
this experiment showed an increase in the expression of CD44 in PBT003 cells
in response to increased concentration of TNF-α. The detailed results are
explained below:
The Effects of Different Concentrations of TNF-α on CD44 Expression of PBT003
Cells
The results of this experiment are shown in Figure 14. PBT003 cells treated with
20 ng/mL of TNF-α show significantly higher expression of CD44 compared to
the control in all different cell densities (P value= 0.0013) Furthermore, in this
experiment, the cells with the highest initial seeding cell number, 5x104 cells,
show the most increase in CD44 expression compared to all other groups.
Furthermore, the trend line of these graphs, shown in Figure 14B, show a dose
dependent response in CD44 expression.
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Figure 14. The effects of TNF-α concentration on CD44 expression on PBT003 cells. A)
Increased concentration of TNF-α caused increased expression of CD44 in these cells. B) The
trend line of these graphs show a dose dependent response in the increased CD44 expression.
C) The One-Way ANOVA test on this experiment shows the increased expression of CD44 in
response increased concentration of TNF-α is significant. (P values = 0.0013)

The Effects of TNF-α on CD44 Expression in Different PBT003 Cell Densities
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Following the same pattern seen in VCAM-1 expression, increased cell density
caused an increase in CD44 expression. However, the control group did not
show any significant increase in CD44 expression in response to increase in cell
density (Figure 15).

The effects of cell density on CD44 expression
25

CD44 (Lum80)

20
Control

15

2.5ng/mL TNF-α
10

5ng/mL TNF-α
10ng/mL TNF-α

5
0
5.00E+02

20ng/mL TNF-α

5.00E+03

5.00E+04

Cell density

Figure 15. the effects of TNF-α on CD44 expression in different PBT003 cell densities

The Effects of TNF-α on Ki67 Expression of PBT003 Cells
Ki67 is a proliferation marker which is shown to be decreased in cells treated with
TNF-α. Figure 16 shows the effects of TNF-α on Ki67 level in PBT003 cells. As is
shown even though the overall trend line in this experiment in negative, indicating
the decrease in Ki67 levels in response to increased TNF-α, this decrease is not
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statistically significant. According to Figure 16B, which shows the trend line of
this experiment, the group of 104 initial cells treated with 20 ng/mL of TNF-α has
positive trend of Ki67 expression in response to increased TNF-α concentration.
Furthermore, this group shows rather fluctuating Ki67 levels in response to
increased levels of TNF-α. The diverse form of this result is Figure 17 which
shows the effects of cell density on Ki67 expression. As shown, increased cell
density as an independent factor have cause increased cell proliferation in these
cells.
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Ki67 (Lum80)

B

Trend line of the effects of TNF-α concentration
on Ki67 expression
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Figure 16. The effects of TNF-α on Ki67 level in PBT003 cells. A) Increased concentration of
TNF-α have caused decrease expression of Ki67 in the treated cells. B) The trend line for the
4
graph is negative showing the decrease in all treated groups except the group with initially 10
cells within which the Ki67 levels were fluctuating. C) The One-Way ANOVA data for these series
of results showed that the decrease in the Ki67 is not significant (P value: 0.2313). The ANOVA
test was also performed between the groups and none of the treated groups showed significant
decrease compared to the control.
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The effects of cell density of Ki67 levels
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5.00E+04

Cell density

Figure 17. The effects of cell density on Ki67 levels of PBT003 cells. Regardless to the TNFα concentration used to treat the cells, the overall tendency of the cells was increased Ki67 levels
in response to increased initial cell density.

In that regard, focusing on the control group without any TNF-α treatment, shown
in figure 18, it is clear that increased cell density alone could also cause an
increase in the expression of Ki67.
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The effects of cell density on Ki67 levels
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Figure 18. The effects of cell density on Ki67 levels.

The Effects of Cell Density on Tumor Dissemination
Interestingly, the non-treated control group of PBT003 cells initially seeded at
5x104 cells also showed satellites, resulted from tumor cell dissemination, after
six days of incubation, emphasizing on the importance of the cell to cell
interactions and the possible chemokines that are secreted as a consequence of
these interactions. Figure 19 shows the VCAM-1 expression of representative
image of control group seeded with 5x104 cells and incubated for six days.
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Figure 19. The effects of cell density on tumor dissemination. The PBT003 control group that
4
primarily seeded with 5x10 cells, disseminated to make a new tumor colony.
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CHAPTER FOUR
DISCUSSION

One of the well-recognized associations in tumor studies is the link between
cancer and inflammation [35] which was first noticed about 150 years ago when
Virchow showed the tendency of cancer occurrence at sites of chronic
inflammation [36]. In 2011, Weinberg for the first time talked about the six
hallmark of the cancer [37] including evading growth suppression, activating
invasion and metastasis, enabling replicative immortality, inducing angiogenesis,
resisting cell death and sustaining proliferation signals. Later studies have shown
the molecular pathways linking inflammation and cancer [38] which resulted in
recognizing inflammation as the “seventh hallmark of cancer”. In the brain,
inflammation occurs as a result of activation of microglia. TNF-α, which is
involved in the regulation of cell survival and proliferation, may therefore,
facilitate cancer development [23]. TNF-α can exert its effects directly or
indirectly in cancer development through its interactions with inflammatory cells
in the tumor microenvironment [23]. In this study we showed that TNF-α,
increases the expression of cell adhesion molecules including VCAM-1 and
CD44 (the receptor of hyaluronic acid) in GBM. Furthermore, we demonstrated
that TNF-α diversely effects the GBM proliferation as Ki67 levels decreased by
increased concentration of TNF-α.
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The first observation of this study was about the GBM dissemination in response
to TNF-α treatment. Figure 9, showing the primary observations after treatment,
indicating that after six days of treatment with 20 ng/mL of TNF-α, GBM cells
have increased their adherence and dissemination. In contrast with control group
that has cells rather in monolayer, in the treatment group the cells have adhered
to each other and disseminated in two different directions, making two new
colonies. The direction of the colony appearance was random and did not follow
any pattern.
The next observation of this study was the increased expression of VCAM-1 in
response to increased concentration of TNF-α (Figure 12). However, the two
treatment groups with lowest initial cell number of 500 and 103, have shown
decreased expression of VCAM-1 in response to treatment with 20 ng/mL of
TNF-α in comparison to their response to 10 ng/mL of TNF-α. This suggest that
cell density and TNF-α both play an important role in the adhesion of the cells. A
possible explanation could be the fact that increased cell-cell interaction could
cause secretion of different cytokines into ECM. Therefore, in all other groups,
PBT003 cells that are initially seeded with 5x103 cell or more, secrete cytokines,
possibly including TNF-α, which enhances the effects of added TNF-α on the
cells. However, the groups with initial cell number of 500 and 103 have not had
the required cell-cell interaction and eventually caused decrease in the VCAM-1
expression. Interestingly, the most satellites were observed with samples treated
with 10 ng/mL of TNF-α. And none of the low-density cells presented these
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satellites. As a matter of fact, the effects of cell density in satellite formation was
so significant that only the control group with the highest cell density (5x103)
showed the presence of satellite (Figure 19). This repeatedly confirms the fact
that cell-cell interaction in the seeded cells with high density possibly cause
secretion of cytokines that effect the cell adhesion. Therefore the media on top of
these cells are collected and preserved for further studies to see the amounts of
different cytokines and chemokines present in the media of treated cells for three
days.
Studying the effects of cell density on VCAM-1 expression under constant
concentrations of TNF-α, Figure 13 shows that, in overall, increase in cell density
caused to an increase in VCAM-1 expression. However, all the treatment groups
reached a plateau with highest initial cell number. This flat trend can be
explained by the effects of TNF-α on Ki67 expression of these cells. As described
in Figure 16, increased concentration of TNF-α decreases the proliferation rate of
GBM. Therefore, cells with lower concentration of TNF-α proliferate more
compared to the cells with higher concentrations. After six days of treatment, the
cell density was not increased evenly in all samples which could explain the drop
of VCAM-1 expression in cells treated with 20 ng/mL of TNF-α.
Another interesting point in our results is the fact that TNF-α which is shown to
cause increase in the level of adhesion molecules in GBM, causes decrease in
the proliferation rate of this tumor cells. However, high proliferation rate is one of
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the major causes of low survival rate in GBM. This confliction might be explained
by the presence of multiple different cytokines and chemokines in the tumor
microenvironment might overcome the negative effects of TNF-α on cell
proliferation. Therefore, the next phase of this study will focus on in vivo analysis
of the effects of TNF-α on the cells in mouse xenograft models.
The end point of this study supports the hypothesis that TNF-α could positively
effects the GBM invasion. However, the signaling pathway regulating the
increased cell adhesion is still not clear. Therefore, the next step of this study
would be to clarify whether TNF-α modulates its effects directly through its
receptor or indirectly through activation of other molecules in the cells. To that
end, one method would be blocking the TNF receptor associated factors (TRAF1 and TRAF-2) and another method would be blocking the present TNF-α in the
culture by TNF-α neutralizing antibody. The results of either of these methods,
alone or in combination, would give us more information and possibly confirm the
results of this study.
The possible downstream effects of TNF-α are through (a) activation of PI3KAKT and NF-κB pathway leading to VCAM-1 expression, or (b) phosphorylation
of ERM through PKC activation which leads to increased HA expression and
consequently CD44 expression. Each of these pathways alone or in combination
could have caused the results seen in this study. Therefore, a next step in this
study would be to clarify whether these two different pathways are working
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independent from each other or related. A method to clarify this, would be
blocking each of these pathways, NF-κB and PKC, separately and in together
and treat the cells with TNF-α. Furthermore, CD44 and VCAM-1 could be the two
possible target molecules to block. Blocking these two molecules could also
confirm if the morphological changes shown in PBT003 cells treated with TNF-α
are actually due to increased expression of VCAM-1 and CD44.
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